menu
    • menu
    [{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Hematology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Hematology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase III","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Chemie \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Berlin Chemie \/ Undisclosed"},{"orgOrder":0,"company":"Aspen API","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Danaparoid sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase III","graph3":"Aspen API","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aspen API \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aspen API \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"RUSSIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Versiti","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase III","graph3":"Versiti","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Versiti \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Versiti \/ National Institutes of Health"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Leo Pharma"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Hematology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Daptomycin","moa":"Cell membrane","graph1":"Hematology","graph2":"Phase III","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"University of Rochester \/ Merck & Co"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Octaplex","moa":"Coagulation factor","graph1":"Hematology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Octaplex","moa":"Coagulation factor","graph1":"Hematology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Nonacog Beta Pegol","moa":"Coagulation factor IX","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Nonacog Beta Pegol","moa":"Coagulation factor IX","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Nonacog Beta Pegol","moa":"Coagulation factor IX","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Nonacog Beta Pegol","moa":"Coagulation factor IX","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Nonacog Beta Pegol","moa":"Coagulation factor IX","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Hematology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Aryogen Pharmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRAN","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Eptacog Alfa","moa":"Coagulation factor VII","graph1":"Hematology","graph2":"Phase III","graph3":"Aryogen Pharmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aryogen Pharmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aryogen Pharmed \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Damoctocog Alfa Pegol","moa":"Coagulation factor VIII","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Turoctocog Alfa Pegol","moa":"Coagulation factor VIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Turoctocog Alfa Pegol","moa":"Coagulation factor VIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Turoctocog Alfa Pegol","moa":"Coagulation factor VIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Turoctocog Alfa Pegol","moa":"Coagulation factor VIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Turoctocog Alfa Pegol","moa":"Coagulation factor VIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Turoctocog Alfa Pegol","moa":"Coagulation factor VIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Turoctocog Alfa Pegol","moa":"Coagulation factor VIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Turoctocog Alfa Pegol","moa":"Coagulation factor VIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Kedrion","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Coagulation Factor X","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kedrion \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University Hospital, Geneva","sponsor":"Sunnybrook Health Sciences Centre","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"University Hospital, Geneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Hospital, Geneva \/ Sunnybrook Health Sciences Centre","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Geneva \/ Sunnybrook Health Sciences Centre"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Factor X","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Factor X","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"The Young Investigator Group of Cardiovascular Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"The Young Investigator Group of Cardiovascular Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Young Investigator Group of Cardiovascular Research \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"The Young Investigator Group of Cardiovascular Research \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Bayer AG"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Catridecacog","moa":"Coagulation factor XIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Catridecacog","moa":"Coagulation factor XIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Catridecacog","moa":"Coagulation factor XIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Catridecacog","moa":"Coagulation factor XIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Catridecacog","moa":"Coagulation factor XIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Catridecacog","moa":"Coagulation factor XIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Catridecacog","moa":"Coagulation factor XIII","graph1":"Hematology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Hematology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Crovalimab","moa":"Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Crovalimab","moa":"Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iptacopan Hydrochloride","moa":"Complement factor B","graph1":"Hematology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Iptacopan Hydrochloride","moa":"Complement factor B","graph1":"Hematology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"X4 Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"X4 Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Stifel","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Stifel","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Stifel"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Empery Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.089999999999999997,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Empery Asset Management","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Empery Asset Management"},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rofecoxib","moa":"Cyclooxygenase-2","graph1":"Hematology","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tremeau Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"European Society for Blood and Marrow Transplantation","sponsor":"Novartis Pharmaceuticals Corporation | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Hematology","graph2":"Phase III","graph3":"European Society for Blood and Marrow Transplantation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"European Society for Blood and Marrow Transplantation \/ Novartis Pharmaceuticals Corporation | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"European Society for Blood and Marrow Transplantation \/ Novartis Pharmaceuticals Corporation | Pfizer Inc"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Idarucizumab","moa":"Dabigatran","graph1":"Hematology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Idarucizumab","moa":"Dabigatran","graph1":"Hematology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Idarucizumab","moa":"Dabigatran","graph1":"Hematology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Idarucizumab","moa":"Dabigatran","graph1":"Hematology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Cooperative Study Group A for Hematology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Hematology","graph2":"Phase III","graph3":"Cooperative Study Group A for Hematology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cooperative Study Group A for Hematology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cooperative Study Group A for Hematology \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"RUSSIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Pegdarbepoetin Beta","moa":"EPO receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Hematology","graph2":"Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"VIETNAM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Darbepoetin alfa","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve","highestDevelopmentStatusID":"10","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Darbepoetin alfa","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Darbepoetin alfa","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRAN","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinnaGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Undisclosed"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blau Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Blau Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"JCR Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"JR-131","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ JCR Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ JCR Pharmaceuticals"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"JCR Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"JR-131","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ JCR Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ JCR Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Iptcaopan","moa":"Factor B (CFB)","graph1":"Hematology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Andexanet","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Andexanet","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals | Population Health Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Andexanet","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals | Population Health Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals | Population Health Research Institute"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Phase III","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Dutch Kidney Foundation | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Phase III","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Dutch Kidney Foundation | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD","highestDevelopmentStatusID":"10","companyTruncated":"University Medical Center Groningen \/ Dutch Kidney Foundation | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Vifor \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Tigermed"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Pierrel","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Vifor \/ Pierrel","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Pierrel"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Corza Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Phase III","graph3":"Corza Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corza Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corza Medical \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"OMRIX BIOPHARMACEUTICALS LTD","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Human Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Phase III","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ OMRIX Biopharmaceuticals Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Ethicon \/ OMRIX Biopharmaceuticals Ltd"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor | Stem cell growth factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Biomm","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"BRAZIL","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Biomm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomm \/ Lupin Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ Lupin Ltd"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Polyethylene Glycolized Human Granulocyte Stimulating Factor","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kexing Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kexing Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"||GEF-H1","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Evive Biotech","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Benegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aurobindo Pharma Limited \/ Evive Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Aurobindo Pharma Limited \/ Evive Biotech"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Spectrum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanmi Pharmaceutical \/ Spectrum Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"LA-EP2006","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sandoz B2B \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Sandoz B2B"},{"orgOrder":0,"company":"European Society for Blood and Marrow Transplantation","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Granulocyte Colony Stimulating Factor","moa":"Granulocyte colony-stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"European Society for Blood and Marrow Transplantation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"European Society for Blood and Marrow Transplantation \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"European Society for Blood and Marrow Transplantation \/ Sanofi"},{"orgOrder":0,"company":"NICHD Global Network for Women's and Children's Health","sponsor":"Thomas Jefferson University | University of North Carolina, Chapel Hill | Kinshasa School of Public Health | University of Alabama at Birmingham | University Teaching Hospital, Lusaka, Zambia | University of Colorado, Denver | Institute of Nutrition of Ce","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Iron","moa":"Hemoglobin (HB)","graph1":"Hematology","graph2":"Phase III","graph3":"NICHD Global Network for Women's and Children's Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NICHD Global Network for Women's and Children's Health \/ Thomas Jefferson University | University of North Carolina, Chapel Hill | Kinshasa School of Public Health | University of Alabama at Birmingham | University Teaching Hospital, Lusaka, Zambia | University of Colorado, Denver | Institute of Nutrition of Ce","highestDevelopmentStatusID":"10","companyTruncated":"NICHD Global Network for Women's and Children's Health \/ Thomas Jefferson University | University of North Carolina, Chapel Hill | Kinshasa School of Public Health | University of Alabama at Birmingham | University Teaching Hospital, Lusaka, Zambia | University of Colorado, Denver | Institute of Nutrition of Ce"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Immune Globulin (Human)","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Hematology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.040000000000000001,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Deep Track Capital","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Deep Track Capital"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Veverimer","moa":"Hydrochloric acid","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FibroGen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ AstraZeneca"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FibroGen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ AstraZeneca"},{"orgOrder":0,"company":"FibroGen","sponsor":"Ruijin Hospital | RenJi Hospital | Chang Zheng Hospital | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Peking University First Hospital | First Affiliated Hospital, Sun Yat-Sen University | First Affiliated Hospital of Zhejiang Unive","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FibroGen \/ Ruijin Hospital | RenJi Hospital | Chang Zheng Hospital | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Peking University First Hospital | First Affiliated Hospital, Sun Yat-Sen University | First Affiliated Hospital of Zhejiang Unive","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Ruijin Hospital | RenJi Hospital | Chang Zheng Hospital | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Peking University First Hospital | First Affiliated Hospital, Sun Yat-Sen University | First Affiliated Hospital of Zhejiang Unive"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ AstraZeneca | Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ AstraZeneca | Astellas Pharma"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Molidustat","moa":"HIF-PH||Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Molidustat","moa":"HIF-PH||Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Molidustat","moa":"HIF-PH||Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Molidustat","moa":"HIF-PH||Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Molidustat","moa":"HIF-PH||Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Molidustat","moa":"Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"AOP Orphan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR||Interferon alpha\/beta receptor","graph1":"Hematology","graph2":"Phase III","graph3":"AOP Orphan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AOP Orphan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AOP Orphan \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Hematology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Hematology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"CAR-NK","moa":"||IL-15-alpha receptor","graph1":"Hematology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Northland Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"NL201","moa":"IL-2\/IL-15 receptor beta-gamma","graph1":"Hematology","graph2":"Phase III","graph3":"Beijing Northland Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Northland Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Northland Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Hematology","graph2":"Phase III","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Shield Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shield Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Beijing Aosaikang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Hematology","graph2":"Phase III","graph3":"Shield Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.059999999999999998,"dosageForm":"Suspension","sponsorNew":"Shield Therapeutics \/ Beijing Aosaikang Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Shield Therapeutics \/ Beijing Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Hematology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Hematology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Max Neeman","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacosmos AS \/ Max Neeman","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Max Neeman"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Pharmacosmos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Baylor College of Medicine \/ Pharmacosmos Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Baylor College of Medicine \/ Pharmacosmos Therapeutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Nemysis","sponsor":"Avia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Financing","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nemysis \/ Avia Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Nemysis \/ Avia Pharma"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Nemysis","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Nemysis","highestDevelopmentStatusID":"10","companyTruncated":"RDC Clinical \/ Nemysis"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Iron III Hydroxide Polymaltose Complex","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Saskatchewan Health Authority \u2013 Regina Area","sponsor":"Saskatchewan Centre for Patient-Oriented Research","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Saskatchewan Health Authority \u2013 Regina Area","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saskatchewan Health Authority \u2013 Regina Area \/ Saskatchewan Centre for Patient-Oriented Research","highestDevelopmentStatusID":"10","companyTruncated":"Saskatchewan Health Authority \u2013 Regina Area \/ Saskatchewan Centre for Patient-Oriented Research"},{"orgOrder":0,"company":"Hull University Teaching Hospitals NHS Trust","sponsor":"Pharmacosmos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Iron Isomaltoside 1000","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Hull University Teaching Hospitals NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hull University Teaching Hospitals NHS Trust \/ Pharmacosmos Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Hull University Teaching Hospitals NHS Trust \/ Pharmacosmos Therapeutics"},{"orgOrder":0,"company":"Fondazione IRCCS Policlinico San Matteo","sponsor":"Italian Group for the study of Inflammatory Bowel Disease","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Sucrosomial Iron","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Fondazione IRCCS Policlinico San Matteo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione IRCCS Policlinico San Matteo \/ Italian Group for the study of Inflammatory Bowel Disease","highestDevelopmentStatusID":"10","companyTruncated":"Fondazione IRCCS Policlinico San Matteo \/ Italian Group for the study of Inflammatory Bowel Disease"},{"orgOrder":0,"company":"American University of Beirut Medical Center","sponsor":"Pharma M SAL","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"LEBANON","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Sucrosomial Iron","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"American University of Beirut Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American University of Beirut Medical Center \/ Pharma M SAL","highestDevelopmentStatusID":"10","companyTruncated":"American University of Beirut Medical Center \/ Pharma M SAL"},{"orgOrder":0,"company":"Consorzio per Valutazioni Biologiche e Farmacologiche","sponsor":"European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ITALY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Hematology","graph2":"Phase III","graph3":"Consorzio per Valutazioni Biologiche e Farmacologiche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Consorzio per Valutazioni Biologiche e Farmacologiche \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"Consorzio per Valutazioni Biologiche e Farmacologiche \/ European Commission"},{"orgOrder":0,"company":"Consorzio per Valutazioni Biologiche e Farmacologiche","sponsor":"European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Hematology","graph2":"Phase III","graph3":"Consorzio per Valutazioni Biologiche e Farmacologiche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Consorzio per Valutazioni Biologiche e Farmacologiche \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"Consorzio per Valutazioni Biologiche e Farmacologiche \/ European Commission"},{"orgOrder":0,"company":"Sanol","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Ferrous II Glycine Sulphate Complex","moa":"Iron stores","graph1":"Hematology","graph2":"Phase III","graph3":"Sanol","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanol \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanol \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Unity Health Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferrous Sulfate","moa":"Iron stores","graph1":"Hematology","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunnybrook Health Sciences Centre \/ Unity Health Toronto","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Unity Health Toronto"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Parsaclisinib","moa":"JAK1","graph1":"Hematology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Bezuclastinib","moa":"||KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ SLR Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ SLR Capital Partners"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Bezuclastinib","moa":"||KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Bezuclastinib","moa":"||KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT*","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Nomacopan","moa":"Leukotriene B4 receptor | Complement C5","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Paulson Investment Company"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Obexelimab","moa":"Low affinity immunoglobulin gamma Fc region receptor II-b | B-lymphocyte antigen CD19","graph1":"Hematology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"Lysine-specific histone demethylase 1","graph1":"Hematology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"OMS721","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"OMS721","moa":"Mannan-binding lectin serine protease 2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"USRC Kidney Research","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"Phosphate","graph1":"Hematology","graph2":"Phase III","graph3":"USRC Kidney Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"USRC Kidney Research \/ Akebia Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"USRC Kidney Research \/ Akebia Therapeutics"},{"orgOrder":0,"company":"AOP Orphan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Anagrelide Hydrochloride","moa":"Phosphodiesterase 3","graph1":"Hematology","graph2":"Phase III","graph3":"AOP Orphan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AOP Orphan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AOP Orphan \/ Undisclosed"},{"orgOrder":0,"company":"AOP Orphan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Anagrelide Hydrochloride","moa":"Phosphodiesterase 3","graph1":"Hematology","graph2":"Phase III","graph3":"AOP Orphan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AOP Orphan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AOP Orphan \/ Undisclosed"},{"orgOrder":0,"company":"AOP Orphan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Anagrelide Hydrochloride","moa":"Phosphodiesterase 3","graph1":"Hematology","graph2":"Phase III","graph3":"AOP Orphan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AOP Orphan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AOP Orphan \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Anagrelide Hydrochloride","moa":"Phosphodiesterase 3","graph1":"Hematology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Anagrelide Hydrochloride","moa":"Phosphodiesterase 3","graph1":"Hematology","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Hematology","graph2":"Phase III","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hyloris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Hematology","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Cardiovascular Diseases, Pakistan","sponsor":"PharmEvo","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"PAKISTAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Hematology","graph2":"Phase III","graph3":"National Institute of Cardiovascular Diseases, Pakistan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Cardiovascular Diseases, Pakistan \/ PharmEvo","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Cardiovascular Diseases, Pakistan \/ PharmEvo"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Hematology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors||Serine protease","graph1":"Hematology","graph2":"Phase III","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AcelRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AcelRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors||Serine protease","graph1":"Hematology","graph2":"Phase III","graph3":"AcelRx Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"AcelRx Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"AcelRx Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"INMUNOVA","sponsor":"Exeltis | Chemo Research | Linical | KLIXAR","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ARGENTINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"INM004","moa":"Shiga Toxin","graph1":"Hematology","graph2":"Phase III","graph3":"INMUNOVA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INMUNOVA \/ Exeltis | Chemo Research | Linical | KLIXAR","highestDevelopmentStatusID":"10","companyTruncated":"INMUNOVA \/ Exeltis | Chemo Research | Linical | KLIXAR"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Bivalirudin","moa":"Thrombin","graph1":"Hematology","graph2":"Phase III","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"The Medicines Company \/ Undisclosed"},{"orgOrder":0,"company":"Ottawa Heart Institute Research Corporation","sponsor":"Boehringer Ingelheim GmbH | Heart and Stroke Foundation | Bayer AG | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Hematology","graph2":"Phase III","graph3":"Ottawa Heart Institute Research Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ottawa Heart Institute Research Corporation \/ Boehringer Ingelheim GmbH | Heart and Stroke Foundation | Bayer AG | Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Ottawa Heart Institute Research Corporation \/ Boehringer Ingelheim GmbH | Heart and Stroke Foundation | Bayer AG | Bristol Myers Squibb"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Hematology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Hematology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"KW-3357","moa":"Thrombin | Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"KW-3357","moa":"Thrombin | Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"KW-3357","moa":"Thrombin | Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Dova Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Dova Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dova Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dova Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hetrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hetrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hetrombopag","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Hetrombopag Olamine","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"SFJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SFJ Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SFJ Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Partnership","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"SFJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SFJ Pharmaceuticals \/ Serb","highestDevelopmentStatusID":"10","companyTruncated":"SFJ Pharmaceuticals \/ Serb"},{"orgOrder":0,"company":"Biovectra Inc","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"Biovectra Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biovectra Inc \/ PhaseBio Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biovectra Inc \/ PhaseBio Pharmaceuticals"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Alfasigma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Alfasigma"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"RTI International | Mid America Heart Institute | National Heart, Lung, and Blood Institute | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Hematology","graph2":"Phase III","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ RTI International | Mid America Heart Institute | National Heart, Lung, and Blood Institute | Genentech","highestDevelopmentStatusID":"10","companyTruncated":"University of Colorado, Denver \/ RTI International | Mid America Heart Institute | National Heart, Lung, and Blood Institute | Genentech"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Tivic Health","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Entolimod","moa":"Toll-like receptor 5","graph1":"Hematology","graph2":"Phase III","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Statera Biopharma \/ Tivic Health","highestDevelopmentStatusID":"10","companyTruncated":"Statera Biopharma \/ Tivic Health"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Peking Union Medical College Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Hematology","graph2":"Phase III","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese SLE Treatment And Research Group \/ Peking Union Medical College Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Chinese SLE Treatment And Research Group \/ Peking Union Medical College Hospital"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Hematology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Hematology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Hematology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Hematology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"8MW0511","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"World Anti-Doping Agency | Anti-Doping Lab Qatar | Sidra Medicine | Laboratorio Antidoping FMSI","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"QATAR","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Autologous Blood","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hamad Medical Corporation \/ World Anti-Doping Agency | Anti-Doping Lab Qatar | Sidra Medicine | Laboratorio Antidoping FMSI","highestDevelopmentStatusID":"10","companyTruncated":"Hamad Medical Corporation \/ World Anti-Doping Agency | Anti-Doping Lab Qatar | Sidra Medicine | Laboratorio Antidoping FMSI"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"BE1116","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Biotest","sponsor":"PRA Health Sciences | Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"BT524","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotest \/ PRA Health Sciences | Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Biotest \/ PRA Health Sciences | Icon Plc"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ITALY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"CUSA-081","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Targeted Medical Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"ESS","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Targeted Medical Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targeted Medical Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Targeted Medical Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferrous Bisglycinate Chelate","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"University of Arizona","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"University of Arizona","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Arizona \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"University of Arizona \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Auerbach Hematology Oncology Associates P C","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Auerbach Hematology Oncology Associates P C","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Auerbach Hematology Oncology Associates P C \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Auerbach Hematology Oncology Associates P C \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Auerbach Hematology Oncology Associates P C","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Auerbach Hematology Oncology Associates P C","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Auerbach Hematology Oncology Associates P C \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Auerbach Hematology Oncology Associates P C \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HHPG-19K","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Plasma-Derived Antithrombin","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Aga Khan University","sponsor":"The Hospital for Sick Children | National Program for Family Planning and Primary Health Care | Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"PAKISTAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Multiple Micronutrients","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Aga Khan University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aga Khan University \/ The Hospital for Sick Children | National Program for Family Planning and Primary Health Care | Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Aga Khan University \/ The Hospital for Sick Children | National Program for Family Planning and Primary Health Care | Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"NIHON PHARMACEUTICAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NPB-06","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"NIHON PHARMACEUTICAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NIHON PHARMACEUTICAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NIHON PHARMACEUTICAL \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PF-06462700","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Recombinant Human Erythropoietin Beta","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Healthgen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Serum Albumin","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Healthgen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthgen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Healthgen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College","sponsor":"Shenyang Sunshine Pharmaceutical Co Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Recombinant Human Thrombopoietin","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Peking Union Medical College","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College \/ Shenyang Sunshine Pharmaceutical Co Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Peking Union Medical College \/ Shenyang Sunshine Pharmaceutical Co Ltd"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"S303 RBCs","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cerus Corporation \/ Undisclosed"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SAL-0951","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SAL-0951","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SAL-0951","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-2004","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR-2004","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Tachosil","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Tachosil","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Takeda Pharmaceutical \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TAK-330","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"UBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"UB-851","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"UBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Z-213","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Z-213","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Z-213","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Hematology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cadrenal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Espero BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Hematology","graph2":"Phase III","graph3":"Espero BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Espero BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Espero BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Caplacizumab","moa":"von Willebrand factor","graph1":"Hematology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Caplacizumab","moa":"von Willebrand factor","graph1":"Hematology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Caplacizumab","moa":"von Willebrand factor","graph1":"Hematology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"}]

    Find Hematology Drugs in Phase III Clinical Development in KOREA, REPUBLIC OF

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Rilzabrutinib

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oral Rilzabrutinib vs Placebo Safety, Efficacy & PK In Warm AIHA ≥18 Years

                            Details : Rilzabrutinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Anemia, Hemolytic, Autoimmune.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 25, 2025

                            Lead Product(s) : Rilzabrutinib

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 ...

                            Details : Sutimlimab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Hemolytic, Autoimmune.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 24, 2021

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Pivotal Data at EHA 2021 reinforces Sutimlimab as A First-in-Class Investigational C1s Inhibitor

                            Details : The CADENZA trial is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sutimlimab in patients with CAD without a recent history of blood transfusion (within the past 6 months).

                            Product Name : Enjaymo

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 11, 2021

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Positive Results from Sanofi's Sutimlimab Pivotal Trial for People with Cold Agglutinin Disease Published in N...

                            Details : Data from the pivotal Phase 3 CARDINAL study demonstrated sutimlimab inhibited C1-activated hemolysis (abnormal destruction of healthy red blood cells) within one week of treatment and had a sustained treatment effect over the course of the study.

                            Product Name : Enjaymo

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 07, 2021

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA issues Complete Response Letter for Sutimlimab, an Investigational Treatment for Hemolysis in Adults with ...

                            Details : The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for sutimlimab, an investigational monoclonal antibody for the treatment of hemolysis in adults with cold agglutinin disease.

                            Product Name : Enjaymo

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 14, 2020

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sanofi Gets Priority FDA Review for Sutimlimab Product

                            Details : Sutimlimab, an investigational monoclonal antibody, targets the underlying cause of hemolysis in CAD by selectively inhibiting complement C1s. If approved, sutimlimab would be the first and only approved treatment for these patients.

                            Product Name : Enjaymo

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 14, 2020

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aspen API

                            Netherlands
                            AAPS
                            Booth #3029
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothAspen API. More than just an API™

                            Lead Product(s) : Danaparoid sodium

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Arg...

                            Details : Danaparoid Sodium is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombocytopenia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 18, 2019

                            Lead Product(s) : Danaparoid sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Aspen API Comapny Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin...

                            Details : BIVV009 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Hemolytic, Autoimmune.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 20, 2017

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin...

                            Details : Sutimlimab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Hemolytic, Autoimmune.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 20, 2017

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sanofi

                            France
                            Pharmtech & Ingredients
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Caplacizumab

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

                            Details : Caplacizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Purpura, Thrombocytopenic.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 25, 2016

                            Lead Product(s) : Caplacizumab

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth